Search results
38 results
- NEWSROOMFuture starts herePlans for the future Falk Campus in Freiburg-Nord finalized.
- NEWSROOMNAFLD: Phase 2a proof of concept study of ZED1227Dr. Falk Pharma and Zedira announce trial start for the treatment of non-alcoholic fatty liver disease. First patient enrolled in April.
- NEWSROOMUEG Week 2022Join us from October 8 – 11 in Vienna on booth no. 43 or virtually!
- NEWSROOMFirst patient treated in phase iib study of Naronapride in patients with gastroparesisDr. Falk Pharma is committed to researching, developing, and launching innovative treatments for digestive and metabolic disorders. We do this both through our own internal teams, and also in…
- NEWSROOMTakeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease TherapyCollaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of Europe, Canada, Australia and China.
- Ulcerative colitisUlcerative colitis Homepage Indications Ulcerative colitis Ulcerative colitis Ulcerative colitis is one of the disorders known as inflammatory bowel disease (IBD). Other disorders within this group of…
- Education centreEducation Centre Homepage Education centre Education centre Welcome to our educational information centre for patients, their families, and all who are interested in diseases of the digestive system.…